ArticleCureus2025
Assessing the Knowledge, Attitude, and Practice of Healthcare Workers on the Herpes Zoster Vaccine in Saudi Arabia: A Cross-Sectional Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Knowledge, Awareness, Attitudes, Acceptance, and Uptake of the Herpes Zoster Vaccine in Saudi Arabia: A Scoping Review.Vaccines · 2026Review
- Saudi Heart Association Position Statement on Adult Vaccinations for Patients With Cardiovascular Diseases.Journal of the Saudi Heart Association · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesHerpes zoster (HZ), known as shingles disease, has several complications that greatly affect elderly and immunocompromised people. Despite evidence for HZ vaccine efficiency and cost-effectiveness, the uptake of the HZ vaccine is lower than that of other common adult vaccines. Strong recommendations by healthcare workers (HCWs) for the HZ vaccine could increase vaccine uptake.
aimThis study aimed to investigate HCWs' knowledge, attitude, and practice of the recombinant zoster vaccine (RZV) in Saudi Arabia and identify gaps and barriers in vaccine recommendation. MATERIALS AND
methodsA cross-sectional, questionnaire-based study was conducted in different hospitals in Riyadh, Saudi Arabia, between December 2023 and March 2024. An electronic self-administered validated questionnaire that assesses the knowledge, attitude, and practice of HCWs regarding the HZ vaccine was sent to all hospital staff. The collected data were organized, entered on an Excel sheet, and statistically analyzed using SPSS software. Pearson's chi-square test and Monte Carlo exact tests were used for data analysis.
resultsA total of 309 HCWs responded to the survey. Family physicians, infectious diseases doctors, and dermatologists are essential to recommend vaccines in Saudi Arabia. In particular, 264 (86.4%) HCWs correctly identified the doses of RZV. However, 148 (47.9%) incorrectly believed that side effects from the first dose were a valid reason not to receive the second dose. Most HCWs (n = 235, 76.1) agreed that they need more direction on which immunocompromised patients are eligible for the RZV vaccine. Most physicians recommend the vaccine for patient groups mentioned in the Advisory Committee on Immunization Practices (ACIP) recommendations. However, 85 (27.5%) recommended the vaccine for healthy adults aged 18-49 years. Ninety-nine (32%) patients declined the vaccine as they did not think they were at risk for developing shingles and 73 (23.6%) declined due to fears of immediate side effects. Among the strategies recommended to increase vaccine uptake are distributing zoster vaccine pamphlets to patients and having a hotline or a website available to discuss zoster vaccination, which were recommended by 255 (82.5%) and 235 (76.1%) HCWs, respectively.
conclusionsPhysicians in Saudi Arabia are generally knowledgeable about the HZ vaccine but need more guidance about ACIP recommendations. The patient reactions to the first dose, the limited vaccine availability, and the perception that RZV has not been adequately studied in immunocompromised patients are among the barriers to vaccine recommendation. Pamphlets regarding the HZ vaccine and a hotline or a website available for discussion about the vaccine are recommended strategies to increase vaccine uptake.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.